- The disease
- Iron overload in the liver occurs when excess iron accumulates in liver tissue, arising in conditions such as hereditary haemochromatosis, thalassaemia, and other anaemias requiring repeated blood transfusions. Left unmonitored, elevated liver iron concentration (LIC) can lead to progressive liver damage. Accurate, non-invasive measurement of LIC is used to guide decisions about iron chelation therapy. Historically, liver biopsy was the reference standard for LIC assessment, but MRI-based methods have been developed as non-invasive alternatives.
- What the asset is trying to do
- FerriScan (and its successor workflow FerriSmart) is a proprietary MRI post-processing service and software that analyses standard MRI scanner data to quantify liver iron concentration non-invasively. Rather than introducing any drug or biological agent, the technology applies a validated image-analysis algorithm to MRI signal data and returns a calibrated LIC measurement in milligrams of iron per gram of liver dry weight. This approach differs from liver biopsy in that it requires no tissue sampling, and differs from general MRI reading in that it uses a specific, validated analytical method rather than qualitative visual assessment. details on the FerriSmart automated software workflow versus the original FerriScan service model.
- What the trial is measuring, and why it matters
- Because FerriScan/FerriSmart is a regulatory-approved diagnostic service rather than a drug in clinical trials, the relevant performance metrics are diagnostic accuracy measures such as agreement with biopsy-derived LIC, repeatability, and reproducibility across MRI scanner types and field strengths. The NCT05899751 registry study listed under this company's trial records relates to high-dose methotrexate and glucarpidase in oncology patients and does not appear to correspond to a FerriScan/FerriSmart evaluation study; that trial's relevance to this asset is . No FerriScan/FerriSmart-specific interventional trial record has been provided in the input data.
- Efficacy benchmarks in this setting
- The non-invasive MRI-based LIC measurement field has published validation data against liver biopsy as the reference standard. St Pierre et al (New England Journal of Medicine, 2005) reported that MRI-based R2 relaxometry for LIC quantification showed strong correlation with biopsy-derived iron concentration across a range of LIC values in that study's patient cohort (per St Pierre et al, NEJM 2005). FerriScan received US FDA 510(k) clearance and CE marking as a medical device for LIC quantification (per Resonance Health public regulatory disclosures ). Biopsy remains a reference comparator in validation literature; direct statistical comparison between FerriScan/FerriSmart figures and other MRI methods requires review of head-to-head studies not provided in the input data.